New Combination Therapy for advanced ovarian cancer under investigation
The international Phase-Phase 3Study (DUO-O) has examined, whether a combination of immunotherapy, chemotherapy, targeted therapy and maintenance therapy that progress of newly diagnosed advanced ovarian cancer delay .
To the study measures more than 1,100 female patients took part, whose tumor no BRCAmutation showed. All received First of all the Standard Treatment with Carboplatin and Paclitaxel, frequently combined with the Antibodies Bevacizumab. Next, were various additional Combination Therapies Tested.
Key Findings finding of the study
The combination of durvalumab (immunotherapy) + chemotherapy + Bevacizumab, followed by a maintenance therapy with durvalumab, Bevacizumab and the PARPinhibitor olaparib, was able to the progression of disease significantly significantly.
In the case of all female patients without BRCAmutation remained the disease in on average 24.2 months stable, compared to 19.3 months under the previous standard treatment.
Especially clear was the effect in female patients with a so-called HRDpositive tumor biology: Here it lay the time until the progress in over three years.
The treatment with durvalumab alone in addition to standard therapy showed , however, no clear benefit .
Survival still unclear
Whether this combination also improve overall survival survival, is currently yet not Sure. In the previous Reports was able to yet none clear survival advantage displayed , but are longer longer are needed.
Side Effects
The Side Effects corresponded to in the Essential to which the individual Medications and were in total comparable to previous experiences.
What means that for patients?
The study shows that a combination of immunotherapy and PARPinhibitor in the Initial Treatment of the advanced Ovarian cancer that Progress the Illness possibly significantly longer delay can, especially in certain tumor biology.
Whether this treatment in the future become in the first-line will, depends , however, on further analyses and approval decisions .
Source: Publication (the article is in English)
